REMOTE ASSESSMENTS FOR ALZHEIMERâS DISEASE COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME - PROJECT SUMMA…
Federal financial assistance recorded from USAspending. This is not a procurement contract.
Research this with AI
Research smarter with AI
Analyze opportunities and compare insights across leading AI models.
ASST_NON_R00AG084738_075 · CHILDRENS HOSPITAL MEDICAL CENTER · Department of Health and Human Services
Compare Multiple AI Models with SmartSoloExplore CaptureIQ IntelligenceAssistance award details
- Assistance award identifier
- ASST_NON_R00AG084738_075
- FAIN
- R00AG084738
- Recipient
- CHILDRENS HOSPITAL MEDICAL CENTER
- Awarding agency
- Department of Health and Human Services
- Funding agency
- Department of Health and Human Services
- Assistance listing (CFDA)
- 93.866
- Total obligated
- $249,000
- Period
- Jun 1, 2024 – Jul 31, 2029
- Fiscal year
- 2026
- Place of performance state
- OH
- Source file
- FY2026_All_Assistance_Full_20261006.zip
Description
REMOTE ASSESSMENTS FOR ALZHEIMERâS DISEASE COGNITIVE DECLINE IN ADULTS WITH DOWN SYNDROME - PROJECT SUMMARY/ABSTRACT THE 75-90% LIFETIME RISK OF ALZHEIMERâS DISEASE (AD) IN DOWN SYNDROME (DS) IS A SIGNIFICANT HEALTH CONCERN FOR THE DS COMMUNITY. DESPITE THE PROGRESS OF LARGE CONSORTIUMS PREPARING THE FIELD FOR UPCOMING CLINICAL TRIALS, THERE ARE CURRENTLY NO VALIDATED REMOTE ASSESSMENT OPTIONS FOR TRACKING AD-RELATED COGNITIVE DECLINE FOR ADULTS WITH DS. REMOTE ASSESSMENT OFFERS NUMEROUS BENEFITS TO PARTICIPANTS AND RESEARCHERS AND WILL SUPPORT RECRUITMENT AND RETENTION IN AD CLINICAL TRIALS, WHICH INVOLVE MANY STUDY VISITS TO ASSESS COGNITIVE AND BEHAVIORAL CHANGES THROUGHOUT A PHARMACEUTICAL OR BEHAVIORAL INTERVENTION. ADDITIONALLY, REMOTE ASSESSMENT WILL ENHANCE THE ACCURACY OF LONGITUDINAL RESEARCH STUDIES BY ALLOWING MORE FREQUENT DATA COLLECTION WITHOUT SIGNIFICANTLY INCREASING PARTICIPANT BURDEN. THIS STUDY WILL FOCUS ON THE LIFE STAGE WHEN AD PATHOLOGY IS BEGINNING (22 â 55 YEARS OLD) TO ENSURE THAT THOSE IN BEGINNING STAGES OF DISEASE PROGRESSION ARE INCLUDED IN THE STUDY SAMPLE. ALL COGNITIVE MEASURES SELECTED TO TRANSITION FROM IN-PERSON TO REMOTE ADMINISTRATION HAVE BEEN SHOWN TO BE PROMISING FOR TRACKING EARLY AD. THE K99 PHASE OF THE STUDY WILL FOCUS ON THE FEASIBILITY AND MODIFICATION OF REMOTE ADMINISTRATION TO ENSURE FAMILIES ARE SATISFIED WITH REMOTE ASSESSMENT PROCEDURES. THE R00 PHASE WILL FOCUS ON EVALUATING THE RELIABILITY AND VALIDITY OF REMOTE MEASURES BY COMPARING PERFORMANCE TO IN-PERSON ASSESSMENTS, INVESTIGATING TEST-RETEST PERFORMANCE, AND MEASURING CHANGE OVER 16 MONTHS. THE R00 PHASE WILL ALSO INCLUDE A BLOOD DRAW TO EXAMINE ASSOCIATIONS BETWEEN COGNITIVE MEASURES AND PLASMA AD BIOMARKERS. METHODOLOGY IS INNOVATIVE IN THAT IT INVOLVES A NEW FRONTIER OF REMOTE ASSESSMENT TOOLS AND INCORPORATES PLASMA BIOMARKERS OF AD TO COMPARE REMOTE AND IN-PERSON COGNITIVE PERFORMANCE TO AD PATHOLOGY. THERE ARE THREE PRIMARY AIMS OF THE PROPOSED